Viking Therapeutics, Inc.Viking Therapeutics, Inc.Viking Therapeutics, Inc.

Viking Therapeutics, Inc.

No trades
See on Supercharts
Market capitalization
‪7.07 B‬USD
−0.91USD
‪−85.90 M‬USD
‪100.41 M‬
Beta (1Y)
2.75

About Viking Therapeutics, Inc.

CEO
Brian Lian
Headquarters
San Diego
Employees (FY)
27
Founded
2012
ISIN
US92686J1060
FIGI
BBG006LGV869
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of VKTX is 63.42 USD — it has decreased by 1.93% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Viking Therapeutics, Inc. stocks are traded under the ticker VKTX.
Viking Therapeutics, Inc. is going to release the next earnings report on Apr 24, 2024. Keep track of upcoming events with our Earnings Calendar.
VKTX stock is 6.75% volatile and has beta coefficient of 2.75. Check out the list of the most volatile stocks — is Viking Therapeutics, Inc. there?
One year price forecast for Viking Therapeutics, Inc. has a max estimate of 138.00 USD and a min estimate of 90.00 USD.
VKTX earnings for the last quarter are −0.23 USD per share, whereas the estimation was −0.22 USD resulting in a −5.00% surprise. The estimated earnings for the next quarter are −0.25 USD per share. See more details about Viking Therapeutics, Inc. earnings.
Yes, you can track Viking Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
VKTX stock has fallen by 9.40% compared to the previous week, the month change is a 3.16% fall, over the last year Viking Therapeutics, Inc. has showed a 198.17% increase.
VKTX net income for the last quarter is ‪−24.61 M‬ USD, while the quarter before that showed ‪−22.53 M‬ USD of net income which accounts for −9.19% change. Track more Viking Therapeutics, Inc. financial stats to get the full picture.
Today Viking Therapeutics, Inc. has the market capitalization of ‪7.07 B‬, it has decreased by 1.90% over the last week.
No, VKTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, VKTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Viking Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
VKTX reached its all-time high on Feb 28, 2024 with the price of 99.41 USD, and its all-time low was 0.88 USD and was reached on Aug 2, 2017.
See other stocks reaching their highest and lowest prices.
As of Apr 19, 2024, the company has 27.00 employees. See our rating of the largest employees — is Viking Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Viking Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Viking Therapeutics, Inc. stock shows the buy signal. See more of Viking Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Viking Therapeutics, Inc. future price: according to them, VKTX price has a max estimate of 138.00 USD and a min estimate of 90.00 USD. Read a more detailed Viking Therapeutics, Inc. forecast: see what analysts think of Viking Therapeutics, Inc. and suggest that you do with its stocks.